The vaccine, made up of two proteins, epidermal growth factor and P64K, is injected into the body to stimulate the immune system of patients with NSCLC to produce corresponding antibodies. The antibody removes epidermal growth factor from the patient’s body, depriving lung cancer cells of nutrients to grow and eventually go into apoptosis. The gene discussed is EGF; the disease is non-small cell lung carcinoma.